Illumina, Inc. (NASDAQ:ILMN – Get Rating) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 4,340,000 shares, an increase of 6.1% from the February 13th total of 4,090,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is currently 3.4 days.
Analyst Ratings Changes
Several analysts recently issued reports on ILMN shares. OTR Global upgraded Illumina from a “mixed” rating to a “positive” rating in a report on Tuesday, December 20th. Cowen decreased their price objective on shares of Illumina from $350.00 to $296.00 in a research report on Tuesday, January 10th. Piper Sandler reissued an “overweight” rating and issued a $290.00 price objective on shares of Illumina in a research report on Wednesday, February 8th. UBS Group decreased their price objective on shares of Illumina from $255.00 to $240.00 and set a “neutral” rating for the company in a research report on Tuesday, February 14th. Finally, Bank of America upped their price objective on shares of Illumina from $210.00 to $230.00 in a research report on Wednesday, February 8th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $249.40.
Insider Transactions at Illumina
In other news, SVP Alexander Aravanis sold 5,398 shares of the company’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total transaction of $1,088,992.52. Following the completion of the sale, the senior vice president now directly owns 2,922 shares in the company, valued at approximately $589,484.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, SVP Alexander Aravanis sold 5,398 shares of the stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total value of $1,088,992.52. Following the completion of the sale, the senior vice president now directly owns 2,922 shares in the company, valued at approximately $589,484.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Aimee L. Hoyt sold 3,917 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $199.06, for a total value of $779,718.02. Following the completion of the sale, the senior vice president now owns 2,881 shares of the company’s stock, valued at $573,491.86. The disclosure for this sale can be found here. Insiders sold a total of 11,186 shares of company stock worth $2,255,837 in the last ninety days. Insiders own 0.13% of the company’s stock.
Institutional Investors Weigh In On Illumina
Illumina Stock Performance
Shares of ILMN stock opened at $224.55 on Friday. The stock has a market capitalization of $35.48 billion, a price-to-earnings ratio of -8.02, a PEG ratio of 8.23 and a beta of 1.15. Illumina has a one year low of $173.45 and a one year high of $371.16. The company’s 50-day simple moving average is $208.86 and its 200-day simple moving average is $208.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.08 and a current ratio of 1.28.
Illumina (NASDAQ:ILMN – Get Rating) last released its quarterly earnings data on Tuesday, February 7th. The life sciences company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.11). The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. Illumina’s revenue was down 9.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. Equities analysts anticipate that Illumina will post 1.41 earnings per share for the current fiscal year.
Illumina Company Profile
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.